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1  | INTRODUC TION
Poor treatment adherence is associated with increased relapse 
frequency, greater healthcare resource utilization, increased 
cost, and poorer patient outcomes than observed in adherent 
patients.1-3 Therefore, it is vital to identify the frequency and un-
derstand the reasons for non-adherence in patients with multiple 
sclerosis (MS).
From the 1990s to 2011, beta-interferons and glatiramer ace-
tate were standard first-line disease-modifying therapies (DMTs) for 
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Objectives: To explore adherence, persistence, and treatment patterns in patients 
with multiple sclerosis (MS) in Finland treated with disease-modifying therapies 
(DMTs) for active MS in 2005-2018.
Materials and Methods: The study cohort was identified using the Drug Prescription 
Register of Social Insurance Institute, Finland. All patients had at least one prescrip-
tion of glatiramer acetate (GA), beta-interferons, teriflunomide, or delayed-release 
dimethyl fumarate (DMF). Adherence was calculated using proportion of days cov-
ered (PDC) (cutoff ≥0.8). Time to non-persistence was calculated by the number of 
days on index DMT treatment before the first treatment gap (≥90 days) or switch and 
analyzed with time-to-event methodology.
Results: The cohort included 7474 MS patients (72.2% female; mean age 38.9 years). 
Treatment switches were steady over 2005-2012, peaked in 2015. PDC means (stand-
ard deviations) were GA, 0.87 (0.17); beta-interferons, 0.88 (0.15); DMF, 0.89 (0.14); 
teriflunomide, 0.93 (0.10). Adherence frequencies were GA, 78.4%; beta-interfer-
ons, 81.3%; DMF, 86.9%; teriflunomide, 91.7%. Logistic regression showed that age 
group, DMT and the starting year, sex, and hospital district independently affected 
adherence. Patients receiving teriflunomide and DMF, males, and older patients were 
more likely to persist on treatment. There was no difference in persistence between 
patients prescribed teriflunomide and DMF, or between GA and beta-interferons.
Conclusions: Oral DMTs had greater adherence and persistence than injectable DMTs.
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active relapsing-remitting MS (RRMS).4,5 When started early in the 
disease course and administered regularly, these injectable agents 
offer reduced numbers of clinical relapses and prevention of new 
lesion formation visualized on MRI.1 During the past decade, several 
DMTs for active RRMS, including the oral agents delayed-release di-
methyl fumarate (DMF), fingolimod, and teriflunomide, have become 
available.4 Although the expansion in treatment options for RRMS is 
welcomed, healthcare professionals are now faced with complicated 
decisions on how to individualize therapy for patients.6
Treatment adherence refers to the extent to which a patient's 
behavior coincides with a treatment plan, whereas persistence is 
the duration over which a patient continues with therapy.7 Several 
factors affect MS medication adherence and persistence, and these 
may vary over the course of the disease.7 For instance, it is reported 
that among patients with MS treated with beta-interferons or glati-
ramer acetate, most discontinuations occur in the first 2 years of 
therapy, and lack of efficacy (30%-50%) and adverse events (22%-
70%) are the most common reasons for treatment termination.7
A systematic review of 24 studies investigating adherence to in-
jectable DMTs (beta-interferons or glatiramer acetate) reported adher-
ence rates ranging from 41% to 88% in patients with MS.2 Reasons 
identified as potential barriers to adherence to injectable DMTs in-
cluded forgetting to inject, patient-perceived lack of efficacy, injection 
anxiety, and adverse effects, including injection site reactions, flu-like 
symptoms, and fatigue.2 A recent retrospective claims analysis per-
formed in Canada reported higher compliance (defined as medication 
possession ratio ≥80%) at 6, 12, and 24 months following treatment 
initiation with the oral agents DMF (70%, 68%, and 56%, respectively), 
teriflunomide (76%, 76%, and 68%, respectively), or fingolimod (75%, 
75%, and 70%, respectively), compared with beta-interferons or glati-
ramer acetate (53%, 47%, and 35%, respectively).8 A number of other 
studies have reported varying degrees of non-adherence in patients 
with MS, with multiple factors identified as influencing factors, includ-
ing patient age, sex, MS history, comorbidities, socioeconomic status, 
and route of treatment administration.9-14
In Finland, an estimated 10 000-11 000 individuals have MS.15 
The impact of the introduction of oral DMTs on treatment adher-
ence and persistence is not known in Finland. The present study will 
utilize nationwide population-based data from the Drug Prescription 
Register of the Social Insurance Institute in Finland to describe base-
line characteristics of patients with MS in Finland treated with DMTs 
for active RRMS and explore adherence, persistence, and treatment 
patterns among these patients.
2  | MATERIAL S AND METHODS
2.1 | Study population
The study cohort included patients with a diagnosis of MS (International 
Classification of Diseases [ICD], 10th Revision code G359; ICD, 9th 
Revision code 340; or ICD, 8th Revision code 340.99) in the Drug 
Prescription Register of the Social Insurance Institute, a Finnish registry 
covering the total population in 20 of 21 hospital districts and 100% 
of drugs prescribed for MS in Finland from January 2005. Of these, 
we identified those with active RRMS, defined as having at least one 
prescription of a DMT from January 2005 to December 2018, includ-
ing glatiramer acetate, beta-interferons, teriflunomide, or DMF. The 
definition for active MS was based on the criteria for reimbursement of 
DMTs for active MS, which includes an Expanded Disability Status Scale 
score < 6.5 and, during the preceding two years, either 2 symptomatic 
relapses or 1 symptomatic relapse and one separate MS lesion on MRI. 
While fingolimod was available during the study period, it is used for 
the treatment of highly active MS and our analyses included only DMTs 
used for treatment of active MS. If fingolimod had been included, other 
DMTs such as natalizumab and alemtuzumab, used during the time 
period 2005-2018 for treatment of highly active MS, would also have 
needed to be included in the analyses. All intravenously administered 
DMTs are hospital products in Finland and are not included in the Drug 
Prescription Register of the Social Insurance Institute; therefore, they 
were not included in these analyses. Patients were identified retrospec-
tively. The index date was the date of the first DMT purchase.
2.2 | Outcome measures
2.2.1 | Baseline demographics
Demographic characteristics collected for each patient included age 
on index date, sex, calendar year of index, and treatment history 
(treatment naive or switch).
2.2.2 | Adherence
Adherence was measured using the proportion of days covered 
(PDC), defined as the number of doses dispensed in relation to the 
dispensing period (or length of clinical benefit based on the label for 
medical claims) during the post-index period, in relation to the num-
ber of days between the index date and the last available day of the 
index DMT during follow-up:
PDC is defined as the total number of days supplied for all pre-
scription fills divided by the number of days between the first and 
last prescription fill plus number of days' supply of the last fill.
2.2.3 | Persistence
The time to non-persistence was calculated by the number of days 
a patient was on the index DMT until the start of the first treatment 
gap (≥90 days) or the switch of treatment.
2.3 | Statistical methods
Summary statistics for baseline demographics were calculated as 
means, medians, and standard deviations (SDs) (continuous meas-
ures), or frequency and percent (categorical measures). Variables 
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found to be associated with adherence or persistence following uni-
variate analysis were included in multivariate models for both adher-
ence and persistence.
Adherence was calculated using a PDC cutoff value of ≥0.8. 
Logistic regression was used to evaluate the differences in the pro-
portion of patients who adhered to their index DMT between the 
groups (age group, sex, DMT cohort, index year, hospital district). 
The pairwise differences of the groups were quantified with odds 
ratios and their 95% confidence intervals.
Persistence was analyzed by applying time-to-event meth-
odology using the Kaplan-Meier approach, together with the 
log-rank test and Cox proportional hazard model. The failure 
event was defined as non-persistence at any time. In case no 
such events were detected, the patient and treatment were 
censored at the time of end of the post-index period. The pair-
wise differences of the groups (age group, sex, and DMT cohort) 
were quantified with hazard ratios and their 95% confidence 
intervals.
All statistical tests tested a two-sided hypothesis of no dif-
ference between groups, at a P-value level of .05. Data were ana-




Baseline demographics are summarized in Table 1. A total of 7474 
patients with MS were included in the cohort, of which 5398 (72.2%) 
were female. Mean (SD) age at index date was 38.9 (10.6) years, and 
the majority of patients (n = 5134; 68.7%) were aged ≤44 years at 
index date.
3.2 | Patterns of DMTs
From 2005 to 2013, two types of DMTs were recorded: beta-inter-
ferons and glatiramer acetate. During this time period, the number of 
patients initiating a DMT ranged from a total of 518 in 2006 to 665 
patients in 2008; approximately one-third of patients initiating a DMT 
were prescribed glatiramer acetate (range over the time period, 29.8%-
41.3%), and two-thirds of patients were prescribed beta-interferons 
(range over the time period, 58.7%-70.2%). Use of teriflunomide 
began in 2014 (n = 132; 22.6%) and DMF in 2015 (n = 468; 42.4%). 
There was a noticeable increase in the total number of patients initiat-
ing or switching a DMT in 2015 (n = 1104) and 2016 (n = 1118) com-
pared with previous years. In 2018, glatiramer acetate was initiated by 
86 (13.5%) patients, beta-interferons by 83 (13.1%) patients, teriflu-
nomide by 185 (29.1%) patients, and DMF by 281 (44.3%) patients.
Duration of DMTs use by individual hospital districts is shown in 
Figure S1 (Supporting Information). Across hospital districts, the ma-
jority of patients (50.0%-65.1%) used DMTs for >2 years through the 
study period. However, the number of patients receiving DMTs in 
districts 22 and 25 was small (31 and 6, respectively). Generally, the 
majority of patients (~52%-100%) used glatiramer acetate and be-
ta-interferons for >2 years. In districts where teriflunomide or DMF 
was used by ≥30 patients, the majority were treated for >1 year.
The number of treatment switches increased steadily from 2005 
(n = 108; 2.0%) to 2012 (n = 259; 4.8%), peaked in 2015 (n = 877; 
16.4%), and then declined in 2018 (n = 431; 8.1%) (Figure 1).
3.3 | Treatment adherence
Between 2005 and 2012, the proportion of patients who were adher-
ent to their DMT ranged from 77.2% to 80.3%; thereafter, the propor-
tion increased, reaching almost 90%. Mean (SD) PDC was >0.8 for all 
four DMT cohorts: teriflunomide, 0.93 (0.10); DMF, 0.89 (0.14); beta-
interferons, 0.88 (0.15); and glatiramer acetate, 0.87 (0.17) (Figure 2). 
The proportions of patients who were adherent to treatment (defined 
as PDC ≥0.8) were 91.7% for teriflunomide, 86.9% for DMF, 81.3% 
for beta-interferons, and 78.4% for glatiramer acetate (Figure 2). In 
the logistic regression analysis, age group, DMT, index year, sex, and 
hospital district each had an independent effect on adherence with 
univariate analysis; these effects were retained when analyzed by 
multivariate analysis (Table 2). Exploratory univariate analysis by DMT 
cohort also showed that hospital district had an effect on adherence 
in the glatiramer acetate and beta-interferon cohorts but not within 
the teriflunomide and DMF cohorts (Table 2). Pairwise comparisons of 
treatments showed a statistically significant difference in adherence 
between all treatments in a univariate analysis (Table 3).
3.4 | Treatment persistence
Patients receiving teriflunomide or DMF were more likely to per-
sist with treatment than those receiving glatiramer acetate or 
TA B L E  1   Baseline characteristics
Baseline characteristics N = 7474
Female, n (%)a  5398 (72.2)
Mean (SD) age at index date, yearsa,b,c  38.9 (10.6)






Abbreviation: SD, standard deviation.
aFive (0.1%) patients were missing data. 
bThe index date was the date of first disease-modifying therapy 
purchase. 
c Patients aged <18 years (n = 57 [0.8%]) were excluded from all 
analyses.  
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beta-interferons; there was no difference in persistence between 
patients taking teriflunomide and DMF or between patients taking 
glatiramer acetate and beta-interferons (Figure 3A). Male patients 
were more likely to persist with treatment than female patients 
(log-rank test for overall difference between sexes, P < .0001) 
(Figure 3B). Analysis by age group showed a decrease in treatment 
persistence with younger age grouping (log-rank test for overall 
difference between age groups, P < .0001) (Figure 3C). Time to 
non-persistence was not statistically significantly different across 
hospital districts for all DMTs, except for beta-interferons (log-rank 
P = .0008; Table S1; Supporting Information).
4  | DISCUSSION
This retrospective population-based study is the first to investi-
gate treatment patterns and treatment adherence and persistence 
among patients initiating DMTs for active RRMS in Finland. Prior 
F I G U R E  1   Proportion of patients who 
switched disease-modifying therapies 
(DMT) for active relapsing-remitting 
multiple sclerosis by year of switch. 
All beta-interferons were considered 
to be one treatment. DMT included 
delayed-release dimethyl fumarate, 
glatiramer acetate, beta-interferons, and 
teriflunomide
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018












































F I G U R E  2   Mean proportion of days 
covered (PDC) and adherence (PDC 
cutoff ≥ 0.8). Error bars for mean PDC 
represent standard deviation (SD). 
Abbreviations: DMF, delayed-release 
dimethyl fumarate; GA, glatiramer 
acetate; IFN, beta-interferon; TER, 
teriflunomide
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to 2014, the number of patients initiating a DMT ranged from 518 
to 665 per year. There were marked increases in the numbers of 
patients initiating a DMT following the introduction of teriflu-
nomide in 2014 and DMF in 2015, with patient numbers almost 
doubling in 2015 (n = 1104) and 2016 (n = 1118), respectively. By 
2018, almost three-quarters (73.4%) of patients initiating a DMT 
started treatment with one of the new oral agents rather than an 
injectable agent. In addition, a rapid increase in the number of 
treatment switches was recorded from 2013 to 2015, also corre-
sponding with the timeframe of oral DMT introduction. This sug-
gests possible patient preference for oral versus injectable agents 
for MS therapy initiation, which would agree with outcomes from 
a web-based conjoint analysis survey performed in the USA; this 
reported a preference for oral daily medications versus biweekly 
subcutaneous or once-weekly intramuscular injections.16
Adherence to DMTs in patients with MS reported in the litera-
ture is highly variable, possibly reflecting the high variability in study 
design and outcome measures.12 Although study designs vary, the 
adherence rates reported here for oral DMTs are comparable with 
those reported by Johnson et al, Duquette et al, and Setayeshgar 
et al and are relatively high compared with other studies.3,8,10,11,14 
In the current study, the proportions of patients adherent to treat-
ment were higher for the two oral agents (2544/2867; 88.7%) than 
for the injectable agents (6982/8697; 80.3%). Also, patients on teri-
flunomide showed better adherence than patients using DMF, which 
may be due to difference in dosing scheme (teriflunomide once daily 
vs. DMF twice daily). In other therapeutic areas, higher dosing fre-
quency has been associated with lower adherence in several,17-20 but 
not in all, 21,22 studies. In addition, persistence to treatment was also 
higher with oral agents versus injectables. Previous claims-based 
studies have reported mixed outcomes regarding adherence and 
persistence for oral and injectable DMTs in patients with MS.3,8,13,14 
In the study by Higuera et al, the probability of adherence to self-in-
jectable agents was dependent upon the side effect profile of the 





OR 95% CI P-value
Age, y <.0001 <.0001
18-34 vs ≥55 0.275 0.216-0.351
35-44 vs ≥55 0.510 0.399-0.653
45-54 vs ≥55 0.753 0.580-0.977
Sex .0048 1.160 1.034-1.300 .0112
Hospital district <.0001 <.0001
Within teriflunomide .6876 NA
Within glatiramer acetate .0090 NA
Within beta-interferons .0019 NA
Within delayed-release dimethyl fumarate .1958 NA
Index yeara  <.0001 <.0001
DMT <.0001 <.0001
Glatiramer acetate vs delayed-release dimethyl fumarate 0.830 0.658-1.048
Teriflunomide vs delayed-release dimethyl fumarate 1.576 1.213-2.049
Beta-interferons vs delayed-release dimethyl fumarate 1.114 0.879-1.411
Abbreviations: CI, confidence interval; DMT, disease-modifying therapy; NA, not available; OR, odds ratio.
aFirst record of DMT prescription. 
bIncluded effects with P < .05 in the univariate analysis. 
TA B L E  3   Univariate logistic regression analysis for differences in adherence between disease-modifying therapies
Therapy comparison Odds ratio
95% confidence 
interval P-value
Teriflunomide vs glatiramer acetate 3.033 2.409-3.819 <.0001
Teriflunomide vs beta-interferons 2.532 2.024-3.166 <.0001
Teriflunomide vs delayed-release dimethyl fumarate 1.660 1.287-2.141 <.0001
Glatiramer acetate vs beta-interferons 0.835 0.748-0.931 .0012
Glatiramer acetate vs delayed-release dimethyl fumarate 0.547 0.465-0.645 <.0001
Beta-interferons vs delayed-release dimethyl fumarate 0.656 0.562-0.765 <.0001
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F I G U R E  3   Time to non-persistence 
to treatment including switch by A, 
disease-modifying therapy, B, sex, and 
C, age. Abbreviations: DMF, delayed-
release dimethyl fumarate; GA, glatiramer 
acetate; IFN, beta-interferons; TER, 
teriflunomide
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agent; lower adherence was reported for agents with injection site 
reactions classified as the most likely side effect than for oral, infus-
ible, or self-injectable DMTs.13
Consistent with previous studies, male sex and older age were as-
sociated with improved adherence and persistence to treatment in this 
study.9,13,14 Given that MS is more prevalent in females than in males, 
lower rates of adherence in female patients likely have a great impact 
in this patient population and highlight an area for further investiga-
tion. It is also possible that lower persistence in young females could 
be related to pregnancy-related treatment gaps. The impact of age on 
treatment adherence in patients with MS is not fully understood.
Shared decision-making between patients and healthcare pro-
fessionals may have a positive effect on adherence to DMT and pa-
tient satisfaction with MS care.23,24 Behavioral, clinical, social, and 
financial aspects should be considered when choosing the DMT, and 
both patient and clinician should have a good understanding of avail-
able treatments.23 Special attention should be paid to active com-
munication between the patient and clinician, as well as to patient 
preferences (eg, route of administration, tolerance, lifestyle, and 
work environment), education, and engagement, as these are im-
portant components of shared decision-making.23 Importantly, the 
majority of patients with MS prefer to have an active role in medical 
decision-making,25 and shared decision-making has not been shown 
to increase anxiety among patients with MS.26 In Finland, shared de-
cision-making is advocated in all hospital districts, but the level of 
patients´ participation may vary individually and between districts.
4.1 | Limitations of the research methods
There were a small number of events in some subgroups. Also, the 
dataset did not contain all desirable information for further investiga-
tion of confounding factors, such as detailed clinical characteristics 
(eg, MS severity or disability level), socioeconomic status, frequency 
of hospitalizations, presence of comorbid conditions, or treatment 
effectiveness. In addition, the use of PDC to evaluate adherence has 
been criticized by some researchers as PDC measures the patterns 
of medication refills rather than actual medication use.14,27 Also, the 
treatment naïve vs switch data were not available in our analysis, as 
the injectable therapies were already in use before 2005 in Finland.
5  | CONCLUSION
In this population-based cohort of patients with MS in Finland, ad-
herence to treatment was better with oral DMTs compared with 
injectable DMTs. Overall adherence to treatment increased from 
2013, which was before oral DMTs for active RRMS became avail-
able and might reflect an increase in general awareness of MS dis-
ease and the importance of treatment adherence. Given its impact 
on patient outcomes and healthcare resources, the importance of 
adherence to DMTs should be discussed as part of patient-centered 
medical care and shared decision-making.
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